Literature DB >> 3125854

Flecainide distribution in human tissues.

R Latini1, A Cavalli, A P Maggioni, A Volpi.   

Abstract

The distribution of antiarrhythmic drugs in human tissues may yield a better understanding of their therapeutic action and side effects. We report tissue distribution of flecainide in a patient who died suddenly while being treated chronically with the drug. Lungs showed the highest concentration of flecainide (143 micrograms g-1 wet tissue); liver, kidney and heart, in decreasing order, have good affinity for the drug. Flecainide was present also in the central nervous system in lower concentrations. The lowest concentration was found in the adipose tissue.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3125854      PMCID： PMC1386410          DOI： 10.1111/j.1365-2125.1987.tb03252.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  5 in total

1.  Plasma and tissue levels of flecainide in rats.

Authors:  D Piovan; R Padrini; M Furlanut; R Moretto; M Ferrari
Journal:  Pharmacol Res Commun       Date:  1986-08

2.  Distribution of propafenone and its active metabolite, 5-hydroxypropafenone, in human tissues.

Authors:  R Latini; S Marchi; E Riva; A Cavalli; M G Cazzaniga; A P Maggioni; A Volpi
Journal:  Am Heart J       Date:  1987-03       Impact factor: 4.749

Review 3.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

4.  Application of a bonded-phase extraction column for rapid sample preparation of flecainide from human plasma for high-performance liquid chromatographic analysis--fluorescence or ultraviolet detection.

Authors:  S F Chang; A M Miller; J M Fox; T M Welscher
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

Review 5.  Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  B Holmes; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546
  5 in total
  3 in total

1.  Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Derek S Steele; Hyun-Seok Hwang; Björn C Knollmann
Journal:  Cardiovasc Res       Date:  2013-03-19       Impact factor: 10.787

2.  Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism.

Authors:  Kosuke Doki; Masato Homma; Keisuke Kuga; Kazutaka Aonuma; Yukinao Kohda
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

3.  Drug-induced acute pneumonitis following initiation of flecainide therapy after pulmonary vein isolation ablation in a patient with mitral stenosis and previous chronic amiodarone use.

Authors:  Henry D Huang; Grzegorz M Pietrasik; Nicholas J Serafini; Parikshit S Sharma; Kousik Krishnan; Richard G Trohman
Journal:  HeartRhythm Case Rep       Date:  2018-11-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.